Abemaciclib
128 interactions 114 explained in plain English 328 cited referencesAbemaciclib is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer. Abemaciclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-po… Read the full Abemaciclib drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Abemaciclib Bacillus Of Calmette And Guerin Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Dengue Tetravalent Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Ensitrelvir Explained Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects Details Abemaciclib Levoketoconazole Recorlev Explained Increased CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related adverse reaction Details Abemaciclib Measles Virus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Mifepristone Korlym Explained Increased CYP3A4 substrate with NTI exposure Details Abemaciclib Mumps Virus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Rubella Virus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Smallpox Monkeypox Vaccine Explained An increased risk of infection by the live vaccine Details Abemaciclib Typhoid Vaccine Typhim VI® Explained An increased risk of infection by the live vaccine Details Abemaciclib Varicella Virus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Yellow Fever Vaccine Stamaril Explained An increased risk of infection by the live vaccine DetailsMajor
Abemaciclib Adagrasib Krazati Explained Increased CYP3A4 substrate exposure Details Abemaciclib Adenovirus Vaccine Type 4, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Adenovirus Vaccine Type 7, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Apalutamide Erleada Explained Reduced CYP3A4 substrate exposure Details Abemaciclib Asciminib Scemblix Explained Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Abemaciclib Avacopan Tavneos Explained Increased exposure to CYP3A4 substrate Details Abemaciclib Belzutifan Welireg Explained Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Abemaciclib Berotralstat Orladeyo Explained Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Abemaciclib Carbamazepine Carbatrol Explained Decreased abemaciclib plasma concentration Details Abemaciclib Ceritinib Zykadia Explained Increased exposure of CYP3A substrate Details Abemaciclib Cholera Vaccine Ipol Explained An increased risk of infection by the live vaccine Details Abemaciclib Clomipramine Anafranil Explained Increased clomiPRAMINE exposure Details Abemaciclib Dabrafenib Tafinlar Explained Reduced sensitive CYP3A4 substrate exposure Details Abemaciclib Daridorexant Explained Increased CYP3A4 substrate with NTI exposure Details Abemaciclib Ebola Zaire Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Elinzanetant Lynkuet Explained Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Abemaciclib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Encorafenib Braftovi Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Abemaciclib Enzalutamide Xtandi Explained Decreased abemaciclib plasma concentration Details Abemaciclib Fedratinib Inrebic Explained Increased CYP3A4 substrate exposure Details Abemaciclib Fexinidazole Explained An increased CYP3A4 substrate exposure Details Abemaciclib Fosphenytoin Cerebyx Explained Decreased abemaciclib plasma concentration Details Abemaciclib Gepotidacin Blujepa Explained Increased CYP3A4 substrate with NTI exposure Details Abemaciclib Givinostat Duvyzat Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects and toxicity Details Abemaciclib Influenza Virus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Ketoconazole Extina Explained Increased abemaciclib exposure Details Abemaciclib Lanreotide Explained Altered exposure to CYP3A4 substrate Details Abemaciclib Lazertinib Lazcluze Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist